In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Pluristem (NASDAQ: PSTI), with a price target of $3. The company’s shares closed on Friday at $1.35.
McCarthy wrote:
“Pluristem announced that the company will release phase 2 data for PLX- PAD cells for the treatment of Intermittent Claudication (IC) on 6/12, which if positive should represent a catalyst for the stock, in our view.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 12.6% and a 45.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
Pluristem has an analyst consensus of Moderate Buy, with a price target consensus of $3.25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.12 and a one-year low of $1.06. Currently, Pluristem has an average volume of 364.8K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions.
